New investigational treatment in migraine prevention

This is a placebo controlled trial to test the efficacy and safety of AMG 301 in the prevention of episodic and chronic migraine. The treatment period is 12 weeks and the total study duration is 35 weeks.

Subjects must be bewteen 18-60 years old and have at least 4 migraine headache days per month. Subjects must have tried at least one triptan medication for migraine and they must also have tried and failed at least one preventative medication for migraine.

Subjects may receive up to $705 for their participation. All study medication and procedures will be provided at no cost to the participants.

Share